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Background. Trypanosoma cruzi causes Chagas disease in the Americas. The outcome of infection ranges from lifelong asymp-
tomatic status to severe disease. Relationship between T. cruzi lineage (TcI-TcVI) infection history and prognosis is not understood. 
We previously described peptide-based lineage-specific enzyme-linked immunosorbent assay (ELISA) with trypomastigote small 
surface antigen (TSSA).
Methods. A novel rapid diagnostic test (RDT; Chagas Sero K-SeT) that incorporates a peptide that corresponds to the TSSA 
II/V/VI common epitope was developed and validated by comparison with ELISA. Patients from Bolivia and Peru, including indi-
viduals with varying cardiac pathology, and matched mothers and neonates, were then tested using Chagas Sero K-SeT.
Results. Chagas Sero K-SeT and ELISA results, with a Bolivian subset of cardiac patients, mothers, and neonates, were in accord. 
In adult chronic infections (n = 121), comparison of severity class A (no evidence of Chagas cardiomyopathy) with class B (elec-
trocardiogram suggestive of Chagas cardiomyopathy) and class C/D (decreased left ventricular ejection fraction; moderate/severe 
Chagas cardiomyopathy) revealed a statistically significant increase in Chagas Sero K-SeT reactivity with increasing severity (χ2 for 
trend, 7.39; P = .007). In Peru, Chagas Sero K-SeT detected the sporadic TcII/V/VI infections.
Conclusions. We developed a low cost RDT that can replace ELISA for identification of TSSA II/V/VI immunoglobulin G. Most 
importantly, we show that response to this RDT is associated with severity of Chagas cardiomyopathy and thus may have prognostic 
value. Repeated challenge with T. cruzi infection may both exacerbate disease progression and boost the immune response to the 
TSSApep-II/V/VI epitope.
Keywords. Chagas disease; cardiomyopathy; prognosis; rapid diagnostic test; Trypanosoma cruzi.
 Trypanosoma cruzi is the agent of Chagas disease, consid-
ered the most important human parasitic disease in Latin 
America. Trypanosoma cruzi is transmitted via contamination 
with infected feces of blood-feeding triatomine bugs through 
mucous membranes, abraded skin, or oral ingestion. The par-
asite can also be transmitted congenitally and by contaminated 
blood components or organs. The initial acute phase may be 
mild and unrecognized, but the disease can be fatal, particularly 
in immunocompromised hosts. The subsequent chronic phase 
may be asymptomatic for life, but around 30% of those infected 
progress to Chagas cardiomyopathy, and a smaller percentage 
may develop gastrointestinal megasyndromes. A recent World 
Health Organization report [1], based on data for 2010, esti-
mates that approximately 5.7 million people in Latin America 
are infected with T. cruzi, of which Bolivia and Peru account for 
approximately 600 000 and 120 000 cases, respectively. Bolivia 
has the highest estimated number of new vector-borne infec-
tions and the highest prevalence.
Trypanosoma cruzi encompasses 6 intraspecies lineages (dis-
crete typing units) TcI–TcVI, with a seventh proposed (TcBat) 
related to TcI [2]. TcI is distributed throughout the Americas 
and frequent among human cases in Mexico, Central America, 
and northern South America, whereas TcII, TcV, and TcVI 
principally circulate in the Southern Cone countries of South 
America. TcIII is widespread in wildlife in South America, 
including armadillos (Dasypus), but rare in humans. TcIV is the 
secondary agent of Chagas disease in Venezuela and, with TcI, 
commonly found in mammals in the United States [2–5].
Association between an individual’s history of T. cruzi lineage 
infection and clinical outcome remains an area of great research 
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interest. For example, certain lineages might more frequently 
be associated with severe chronic disease, such as gastrointes-
tinal manifestations [3, 6]. However, the sequestration and rep-
lication of T. cruzi in host tissues, low circulating parasitemias, 
and selection of isolates in cultures hamper the identification of 
representative lineages by direct genotyping of clinical samples.
There are many commercial and in-house diagnostic sero-
logical tests for T. cruzi infection, with diverse sensitivities and 
ease of use [7]. To date, the mucin trypomastigote small surface 
antigen (TSSA), expressed on the bloodstream trypomastigote 
form, has been the only T. cruzi antigen shown to be applic-
able to lineage-specific serology [8–10]. The protein core of 
TSSA contains remarkable polymorphism, in which TcI, TcIII, 
and TcIV have their own lineage-specific sequences. The TcII 
sequence is shared with TcV/VI except that 1 haplotype of the 
heterozygous TcV/VI allele is specific to these hybrid lineages 
[11]. Previously, we used synthetic peptides representing the 
lineage-specific TSSA epitopes as antigens for serology with 
sera of chronic Chagas disease patients from South American 
countries [9]. We observed that the peptide representing the 
TSSA epitope common to TcII/V/VI (TSSApep-II/V/VI) 
had a high level of recognition by immunoglobulin (Ig) G 
from patients in Southern Cone countries, including Bolivia. 
Furthermore, a higher proportion of TSSApep-II/V/VI sero-
positive patients from Brazil had electrocardiogram (ECG) 
abnormalities compared with patients who were TSSApep-
II/V/VI seronegative [9].
Our objectives were to adapt TSSApep-II/V/VI–specific 
serology to a novel, low-cost, point-of-care, lateral flow immun-
ochromatographic rapid diagnostic test (RDT); to compare the 
RDT to the lineage-specific peptide enzyme-linked immuno-
sorbent assay (ELISA); and to apply the RDT to serology of clin-
ically assessed T. cruzi-infected Bolivian and Peruvian patients 
previously untested by lineage-specific serology.
METHODS
Origin of Samples
The samples originated from previously reported studies 
[12–17]. Trypanosoma cruzi infection was defined by positive 
results by ≥2 conventional serological tests. 
Set 1, Bolivia [12, 13]: comprised maternal and cord blood 
from Santa Cruz, a city without vector-borne T. cruzi transmis-
sion, and from the smaller city of Camiri not far from villages 
with triatomine infestation. 
Set 2, Bolivia: samples were from a study of potential cardiac 
biomarkers in adults in Santa Cruz. Data included New York 
Heart Association (NYHA) class and cardiac severity stages A, 
B, C, and D, as defined by Okamoto et al [14]. All patients in 
stages C and D (defined by moderately and severely decreased 
left ventricular ejection fraction, analyzed together as C/D) had 
echocardiogram data. Those in NYHA class 0 (no restrictions 
on exercise tolerance) with normal ECG readings but no echo 
data were included in stage A (no evidence of cardiomyopathy); 
such individuals are considered unlikely to have significant 
abnormalities on ECG [18]. If the ECG reading showed abnor-
malities suggestive of Chagas cardiomyopathy, we included 
the patient in stage B. Some patients thus classified as stage B 
might have been assigned to stage C/D if the echo had been 
performed, but this misclassification would bias the cardiomy-
opathy analysis toward the null hypothesis. Participants with-
out echo data and with ECG abnormalities not characteristic 
of Chagas cardiomyopathy were excluded from these analyses.
Set 3, Peru: specimens were from 2 studies in and near 
Arequipa in southern Peru [15, 16] and a community study in 
Cajamarca Department in northern Peru [17].
Ethics
The following institutional review boards granted ethical 
approval:
Set 1.  Johns Hopkins Bloomberg School of Public Health 
(JHBSPH, United States), Hospital Universitario Japonés 
(Bolivia), Universidad Católica Boliviana (UCB, Bolivia), 
Universidad Peruana Cayetano Heredia (UPCH, Peru), 
Asociación Benéfica Proyectos en Informatica, Salud, Medicina 
y Agricultura (A. B. PRISMA, Peru), and the Centers for Disease 
Control and Prevention (United States). Each woman provided 
written informed consent for herself and her infant.
Set 2.  UCB, A.  B. PRISMA, and JHBSPH. All participants 
provided written informed consent.
Set 3. Study [15]: JHBSPH, UPCH, University of Pennsylvania 
(Penn) Study [16]: JHBSPH, A.B. PRISMA Study [17]: A.B. 
PRISMA, Penn. All participants provided written informed 
consent.
Additional approval: serum collection and secondary data 
analysis was approved under the ChagasEpiNet protocol by the 
London School of Hygiene and Tropical Medicine.
Lineage-Specific Peptide ELISA
Peptides TSSApep-II/V/VI, -III, -IV, and -V/VI represent-
ing residues 37–52 in the TSSA protein of those lineages and 
T.  cruzi TcII lysate (IINF/PY/00/Chaco23cl4) were used in 
ELISA as described previously [9].
Chagas Sero K-SeT RDT
This novel RDT was developed in the laboratories of Coris 
BioConcept. Plastic cassettes were constructed with a nitrocel-
lulose membrane, sample, conjugate, and absorbent pads backed 
with a plastic strip. The cassette had 2 windows: a buffer applica-
tion well and a test/reading window where the sample application 
zone is also located (Figure 1). The nitrocellulose membrane was 
sensitised with TSSApep-II/V/VI (GTENKPATGEAPSQPG) 
coupled to avidin. Depending on sample type, 2–3 µL of sam-
ple was applied to the sample application zone, then buffer was 
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added in the buffer well. Immunoglobulin (IgG) antibodies 
from the sample that migrated over the nitrocellulose mem-
brane reacted with the avidin-immobilized peptide. The pro-
tein G-gold conjugate rehydrated by the buffer recognized the 
TSSApep-II/V/VI–bound IgG, resulting in a red–purple colored 
band. A control line ensured that sample and conjugate migra-
tion had occurred. Tests were read after 15 minutes and scored 
as either positive (colored test and control lines) or negative (col-
ored control line only) and photographed.
Statistical Analysis
Categorical variables were compared using χ2 or Fisher exact 
test, as appropriate. Continuous variables were compared using 
the Wilcoxon ranked sum test.
RESULTS
Comparability of Lineage-Specific ELISA and Chagas Sero K-SeT RDT
A subset of samples from set 1 (5 matched pairs of maternal and 
cord blood) and set 2 (n = 15) were assayed using TSSApep line-
age-specific ELISA and Chagas Sero K-SeT RDT. Of the samples 
in this subset, all from set 1 and 11 from set 2 were seropositive 
by conventional serology (CS+). Results from the 2 assays were 
concordant (Figure  1). Both assays detected maternal IgG 
transferred transplacentally. Thus, based on this subset of sam-
ples, the 2 lineage-specific assays, Chagas Sero K-SeT RDT and 
ELISA, performed at least equally well. Therefore, only Chagas 
Sero K-SeT RDT was used for the remaining samples.
Set 1: Paired Maternal and Cord Blood
Specimens from 131 CS+ and 12 CS− women were tested. The 
mean maternal age was 27.6  years (standard deviation [SD] 
7.2). RDT results were positive in 68.7% (57/83) and 66.7% 
(32/48) of CS+ mothers from Camiri and Santa Cruz, respec-
tively (P = .81 for site comparison); however, there is active pop-
ulation migration at both sites. There was 100% concordance 
between maternal and cord blood by Chagas Sero K-SeT RDT 
(36 RDT positive and 21 RDT negative in both specimens). 
RDT results did not differ by infection status of the infant 
(4/6 infected vs 84/124 uninfected infants of infected mothers; 
P  =  1.0 by Fisher exact) or by maternal age (P  =  .34). There 
was no significant difference in the frequency of positive RDT 
for the small number of women with ECG changes suggestive 
Figure 1. Concordance of Chagas Sero K-SeT and TSSApep enzyme-linked immunosorbent assay (ELISA). Representative samples from set 1 (matched mother–neonate) 
and set 2 (adult chronic infection) assayed using TSSApep ELISA and Chagas Sero K-SeT gave corresponding results for TSSApep-II/V/VI reaction, with 1 negative/borderline 
ELISA positive by rapid diagnostic text (pair m1 n1). Set 2, sample 6, was previously shown to be Trypanosoma cruzi seronegative. The A490 reading is for TSSApep-II/V/VI 
reactivity by ELISA and is the mean of duplicate assay plates.
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of Chagas cardiomyopathy compared with those with normal 
ECG (5/11 vs 65/95; P = .17 by Fisher exact).
Set 2: Adult Chronic Infection
A total of 121 CS+ and 27 CS− specimens were tested. Among 
CS+ patients, 73 (52.9%) were male and the mean age was 
57.1  years (SD 12.3). CS− participants were significantly 
younger (mean age, 50.5  years; P  =  .008) and slightly less 
likely to be male (40.7% [11/27]; P = .29). There was no dif-
ference in the prevalence of positive RDT by participant age 
(P  =  .91) or sex (P  =  1.0). However, 52.5% (21/40) of those 
without evidence of cardiomyopathy had positive RDT results 
compared with 74.1% (60/81) of those with cardiomyopathy 
(stage A  vs stages B/C/D combined; P  =  .02). There was a 
significant trend for increasing frequency of RDT reactivity 
with increasing cardiac severity stage (P = .007 based on χ2 for 
trend; Figure 2).
Set 3: Peruvian Specimens
A total of 84 specimens (65 CS+ and 19 CS−) were tested, 61 
from southern Peru and 23 from northern Peru. The mean 
age of participants was 41.7 years (SD 19.8) and 59.5% were 
female. There was no significant difference in the prevalence 
of positive RDT in CS+ specimens from southern vs north-
ern Peru (8.2% [4/49] vs 18.8% [3/16]; P  =  .35). However, 
the prevalence of positive RDT was markedly lower in Peru 
compared with Bolivia (10.8% [7/65] vs 66.9% [180/269]; 
P < .0001).
Of 58 CS−negative specimens, 2 (1 from Peru and 1 from 
Bolivia set 2)  were detected by Chagas Sero K-SeT RDT as 
TcII/V/VI seropositive, corresponding to a specificity of 96.5% 
(95% confidence interval, 87.9–99.6) compared with conven-
tional serology.
DISCUSSION
The genetic lineages of T.  cruzi are remarkably diverse. 
Understanding the relationship between an individual’s his-
tory of T. cruzi lineage infection and clinical outcome has been 
a research interest since the discovery of disparate geographi-
cal distributions of TcI and TcII between patients in Venezuela 
and Brazil, where prevalence of gastrointestinal syndromes also 
appeared strikingly divergent [3, 6]. Nevertheless, it is clear that 
Chagas cardiomyopathy occurs in TcI endemic regions and that 
TcI may cause severe disease in the immunocompromised [19]. 
Multiple potential confounders may complicate the association 
between T. cruzi diversity and clinical prognosis of Chagas dis-
ease, including human genetic diversity, immune competence, 
and exposure to coinfections [3]. Development of lineage-spe-
cific serology provides an alternative approach to studying the 
geography, epidemiology, and clinical relevance of the T. cruzi 
lineages, partially circumventing limitations of selective isola-
tion and genotyping of T. cruzi strains.
The antigenicity of the TcII/V/VI isoform of TSSA has 
been established by serology of patients and animals in 
conjunction with bioinformatic and epitope mapping [8, 9, 
20, 21]. Consistent with the absence of the TcII/V/VI epi-
tope from all other T.  cruzi lineage genomes, we demon-
strated the serological specificity of TSSApep-II/V/VI and 
the absence of response in control infections [9]. However, 
because the sensitivity of TSSApep-II/V/VI serology is not 
100%, seronegativity does not prove the absence of TcII/V/VI 
infection or that the agent of Chagas disease in such seron-
egative patients is TcI. Nevertheless, we have observed that 
the Chagas Sero K-SeT RDT consistently detected TSSApep-
II/V/VI ELISA positives and, as noted here, occasional add-
itional sera with negative/borderline ELISAs (Figure  1 [9], 
and unpublished data).
Previous lineage-specific serology with TSSA has used 
Western blot, ELISA, or other complex protocols that require 
skilled technical staff, laboratory facilities, and usually a cold 
storage chain [8–10]. We developed the Chagas Sero K-SeT 
RDT to overcome these practical and expensive issues, yet 
still allow for reliable and robust detection of IgG specifically 
recognizing TSSApep-II/V/VI. We show here that the Chagas 
Sero K-SeT RDT can replace ELISA for TSSApep-II/V/VI 
serology, detect lineage-specific IgG that is transferred across 
the placenta from an infected mother (set 1), is associated with 
higher likelihood of cardiac findings (set 2), and functions in 
geographical regions where some low anti-T cruzi antibodies 
have been reported (set 3).
Figure 2. Association between Chagas cardiomyopathy severity and response to 
Chagas Sero K-SeT. Upper panel: cardiac severity stages (A–D) and Chagas Sero 
K-SeT result, where A = normal echocardiogram (ECG) plus normal left ventricular 
ejection fraction (LVEF) or New York Heart Association = 0 (in absence of echo), 
B = ECG abnormalities suggestive of Chagas cardiomyopathy, and C/D = decreased 
LVEF. Stratum odds ratio χ2 for trend 7.39; P =  .007. Lower panel: graphical rep-
resentation of these data.
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To our knowledge, this is the first report of lineage-specific 
serology with matched maternal and cord blood. Bisio et  al 
[22] found seropositivity to recombinant TSSA-II/V/VI among 
pregnant women from Argentina, Bolivia, and Paraguay but did 
not assess transplacental transfer of specific IgG. Genotyping 
of T. cruzi from neonates born to Bolivian mothers identified 
predominantly TcV; however, no association has been shown 
between T. cruzi lineage and congenital transmission risk [23]. 
Balouz et al [10] used recombinant TSSA-II/V/VI in serologi-
cal assessment of treatment outcome in pediatric Chagas dis-
ease, indicating that this antigen could detect seronegativization 
sooner than conventional serological tests. While the Chagas 
Sero K-Set RDT does not solve the problem of diagnosing con-
genital infection at birth, its capacity to detect equal levels of 
anti-TSSA II/V/VI IgG in the mother and in cord blood illus-
trates its reliability, reproducibility, and wider potential as a 
consistent diagnostic assay.
Our analysis of results from older adults in Santa Cruz (set 
2) demonstrates a significant association between the prevalence 
of positive results by this RDT and increasing severity of cardio-
myopathy. We found evidence of a similar relationship in a pre-
vious study in southern Brazil, in which ECG abnormalities were 
more frequent among TSSApep-II/V/VI seropositive patients 
compared with TSSApep-II/V/VI seronegative patients [9]. 
Cytokine profiles of Chagas patients may be alternative signs of 
cardiomyopathy [14] but are not currently available as consistent 
indicators of prognosis or amenable to point-of-care rapid tests.
The mechanism underlying the association we observed 
between positive RDT and cardiac disease severity may be 
related to repeated parasite exposure over time. Investigators 
have previously postulated that repeated T. cruzi superinfection 
in those living in infested houses may increase inflammatory 
responses and the consequent risk of immunologically medi-
ated cardiac damage [24]. Thus, repeated challenge with T. cruzi 
infection in triatomine-infested dwellings may both enhance the 
inflammatory response and boost the immune response to the 
TSSApep-II/V/VI epitope. Prolonged residence in an infested 
house was associated with increased risk of ECG abnormalities 
in our earlier analysis of data from Bolivian mothers [12].
We found a much lower prevalence of TcII/V/VI seropos-
itivity among Peruvian patients than Bolivian patients. These 
results are in agreement with the widely reported low preva-
lence of these lineages outside the Southern Cone [2, 3, 25]. 
However, theoretically TcII/V/VI seropositivity might be 
partially influenced by reported low anti-T.  cruzi immune 
responses among patients in southern Peru [16, 26]; even when 
rare, the TSSApep-II/V/VI RDT has the capacity to detect such 
infections.
Here, we have produced a highly informative, low-cost, point-
of-care, lineage-specific RDT. Thus, there is justification to search 
for antigens applicable to each of the T. cruzi lineages, as well as 
for improved RDTs that are equally applicable across all diverse 
T. cruzi endemic regions. Furthermore, we have shown that the 
Chagas Sero K-Set RDT may provide an indicator of presence 
and risk of Chagas cardiomyopathy. We have proposed that this 
is explicable by concomitant exacerbation of disease and boost-
ing of immune response to the TSSApep-II/V/VI epitope.
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